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p27Kip1Podocytes are terminally differentiated cells of the glomerularﬁltration barrier that reactwith hypertrophy in the
course of injury such as inmembranous nephropathy (MGN). The neuronal deubiquitinase ubiquitin C-terminal
hydrolase L1 (UCH-L1) is expressed and activated in podocytes of human and rodentMGN. UCH-L1 regulates the
mono-ubiquitin pool and induces accumulation of poly-ubiquitinated proteins in affected podocytes. Here, we
investigated the role of UCH-L1 in podocyte hypertrophy and in the homeostasis of the hypertrophy associated
“model protein” p27Kip1. A better understanding of the basic mechanisms leading to podocyte hypertrophy
is crucial for the development of speciﬁc therapies in MGN. In human and rat MGN, hypertrophic podocytes
exhibited a simultaneous up-regulation of UCH-L1 and of cytoplasmic p27Kip1 content. Functionally, inhibition
of UCH-L1 activity and knockdown or inhibition of UCH-L1 attenuated podocyte hypertrophy by decreasing
the total protein content in isolated glomeruli and in cultured podocytes. In contrast, UCH-L1 levels and activity
increased podocyte hypertrophy and total protein content in culture, speciﬁcally of cytoplasmic p27Kip1. UCH-L1
enhanced cytoplasmic p27Kip1 levels by nuclear export and decreased poly-ubiquitination and proteasomal deg-
radation of p27Kip1. In parallel, UCH-L1 increased podocyte turnover, migration and cytoskeletal rearrangement,
which are associatedwith known oncogenic functions of cytoplasmic p27Kip1 in cancer.We propose that UCH-L1
induces podocyte hypertrophy in MGN by increasing the total protein content through altered degradation and
accumulation of proteins such as p27Kip1 in the cytoplasm of podocytes. Modiﬁcation of both UCH-L1 activity and
levels could be a new therapeutic avenue to podocyte hypertrophy in MGN.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Glomerular podocytes are highly specialized cells with a complex
cytoarchitecture. Their most prominent features are interdigitated
foot-processes with ﬁltration slits in between. These are bridged by
the slit-diaphragm,whichplays amajor role in establishing the selective
permeability of the glomerular ﬁltration barrier [1]. Podocytes are
terminally differentiated [2] and respond to injury with foot-process re-
traction, hypertrophy and loss, which ultimately results in proteinuria.
Podocyte hypertrophy occurs in human membranous nephropathydicine, Nephrology, University
0246 Hamburg, Germany.
rg.de (C. Meyer-Schwesinger).(MGN) and in the corresponding ratmodel of passive Heymannnephri-
tis (PHN) [3]. Podocyte hypertrophy is considered as a maladaptive at-
tempt to cover denuded areas of the glomerular basement membrane
[4]. The mechanisms of podocyte hypertrophy in MGN are poorly
deﬁned.
We recently described the de novo expression of ubiquitin
C-terminal hydrolase-L1 (UCH-L1) in podocytes in human [5] and
rodent membranous glomerulonephritis [6] and suggested that UCH-L1
is involved in the accumulation and aggregation of poly-ubiquitinated
proteins in injured podocytes [6]. UCH-L1 represents one member of
the ubiquitin carboxy-terminal hydrolase (UCH) family [7]. UCH enzymes
belong to the de-ubiquitinating enzymes of the ubiquitin-proteasome
pathway. Besides de-ubiquitinating enzymes, this pathway comprises
enzymes that ubiquitinate target proteins and the 26S proteasome
complex, which selectively degrades poly-ubiquitinated proteins. De-
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conjugation by removing the poly-ubiquitin chain from conjugated pro-
teins prior to their degradation by the proteasome [8,9]. Biochemically,
UCH-L1 plays a role in proteasomal protein degradation via two opposing
enzymatic activities. Firstly, UCH-L1 hydrolyses ubiquitin pro-proteins
and small ubiquitin-adducts, which results in the generation of free mo-
nomeric ubiquitin, the active component of the ubiquitin-dependent pro-
teolytic system [10,11]. Secondly, UCH-L1 has been shown to have a
dimerization dependent ubiquitin–ubiquitin ligase activity [12]. Recent
publications have demonstrated that some biological effects of UCH-L1
are based on its ability to bind to and thus stabilize mono-ubiquitin
[13]. Little is known regarding UCH-L1 speciﬁc substrates or biological ac-
tivity in vivo.
Renal cell hypertrophy is thought to be in partmediated by cell cycle
arrest, either at the G1/S phase resulting in increased cell size, and
protein and RNA contents [14] or in the G2 phase subsequent to DNA
replication resulting in bi- or multinucleated cells [4,15]. Cell cycle pro-
gression is regulated by the accumulation of cyclins, which bind to and
activate different cyclin-dependent kinases, which in turn are regulated
by cyclin-dependent kinase inhibitors. The cyclin-dependent kinase in-
hibitor p27Kip1 is a major regulator of podocyte hypertrophy in vitro in
response to hyperglycemia [16] and stretch [17] and in vivo in a
model of type 2 diabetes [18]. P27Kip1 levels increase in passive
Heymann nephritis [19]. Therefore p27Kip1 was suggested to function
as a regulatory switch of podocyte hypertrophy by inhibition of cell
cycle progression through the G1/S phase. Multiple posttranscriptional
mechanisms regulate p27Kip1, such as translation [20] or proteasomal
degradation [21,22].
UCH-L1 has been described as a tumor oncogene [23–25] and as a
tumor suppressor gene inﬂuencing p53 and p27Kip1 [26]. UCH-L1 inter-
actswith p27Kip1 through the generation of a heteromeric complexwith
the Jun activation domain-binding protein 1 (JAB-1) in ovaries [27] and
lung cancer cells [28]. Nuclear translocation of both UCH-L1 and JAB-1
coincides with reduced nuclear levels of p27Kip1, proposing that UCH-
L1may contribute to p27Kip1 degradation via its interaction and nuclear
translocation with JAB-1 [28] in tumor cells.
The aim of this study was to analyze whether UCH-L1 induces
podocyte hypertrophy by protein stabilization of proteins like/such as
p27Kip1 in human and rodent membranous nephropathy and in cul-
tured podocytes.2. Results
2.1. In human MGN UCH-L1 is upregulated and p27Kip1 localizes to the
cytoplasm in hypertrophic podocytes
In human membranous nephropathy (MGN), swollen podocytes
with increased cell body area impose along the glomerular ﬁltration
barrier by light microscopy (Fig. 1A). Recently we demonstrated that
UCH-L1 is strongly expressed in podocytes in patients with MGN [5].
Immunohistochemistry showed that UCH-L1 was preferentially
expressed in hypertrophic podocytes in MGN (Fig. 1B, a). Podocyte hy-
pertrophy is thought to be mediated by p27Kip1. We therefore analyzed
whether p27Kip1 expressionwas changed inMGN in comparison to con-
trol. Stainings against p27Kip1 demonstrated an increased expression of
p27Kip1 in the cytoplasm of podocytes inMGN (Fig. 1C). Confocal analy-
ses showed that both UCH-L1 and p27Kip1 were expressed in the same
hypertrophic podocytes (Fig. 1D). Both proteins co-localized in the
nuclei and in the cytoplasm, suggesting that UCH-L1 might induce
podocyte hypertrophy through altered p27Kip1 homeostasis in injured
podocytes. We therefore analyzed, whether p27Kip1 was regulated on
the transcriptional or post-translational level in MGN. Quantitative
PCR (Fig. 1E) against p27Kip1 inmicro-dissected glomeruli from patients
withMGN in comparison to living donors demonstrated that transcripts
of p27Kip1 did not change signiﬁcantly.2.2. In experimental MGN both UCH-L1 and p27Kip1 are upregulated in
hypertrophic podocytes
Similar to human MGN, the well-established rat model of MGN
called passive Heymann nephritis (PHN) also induced swollen
podocytes (Fig. 2A, c, d) with increased cell body area by lightmicrosco-
py (Fig. 2B). Hypertrophy, which is deﬁned as an increase of cell size in
conjunction with increased protein content and stable gDNA content,
was further quantiﬁed bymeasuring protein to gDNA ratio in glomerular
lysates after RNAse treatment. The protein to gDNA ratiowas signiﬁcant-
ly increased in nephritic glomeruli (Fig. 2C), indicating glomerular cellu-
lar hypertrophy. Immunohistochemical stainings demonstrated that
UCH-L1 was strongly and preferentially expressed in hypertrophied
podocytes in PHN (Fig. 2D, b). Again, as in MGN, UCH-L1 expression
correlated with p27Kip1 expression in hypertrophic podocytes in PHN.
Furthermore, p27Kip1 expression was pronounced in the cytoplasm of
podocytes in PHN (Fig. 2E). Quantiﬁcation of p27Kip1 content in isolated
glomeruli exhibited elevated p27Kip1 protein levels in PHN by WB
(Fig. 2F) and by ELISA (Fig. 2G) 18 days after disease induction, albeit,
glomerular p27Kip1 transcript levels were not increased on day 18 after
disease induction (Fig. 2H). Double-stainings demonstrated UCH-L1
and p27Kip1 co-expression in hypertrophied podocytes in PHN (Fig. 2I).
Cytoplasmic p27Kip1 staining was prominent in podocytes of PHN rats,
whereas mostly a nuclear p27Kip1 signal was observed in podocytes of
control rats.
Taken together, these data suggest that in human and rodent MGN
UCH-L1 expressionwas increased in hypertrophic podocytes and corre-
lated with increased p27Kip1 protein expression and cytoplasmic
localization.
2.3. Podocyte hypertrophy and glomerular protein content are regulated by
UCH-L1 in experimental MGN
We therefore asked whether inhibition of UCH-L1 hydrolase func-
tion in PHN reduced the morphologic and biochemical parameters of
podocyte hypertrophy. PHN and control rats were treated for 14 days
with LDN57444, a selective inhibitor of UCH-L1 hydrolysis function
[6]. Light-microscopic evaluation demonstrated a decreased swelling
of podocytes in PHN rats treatedwith LDN57444 (Fig. 3A, d). Quantiﬁca-
tion of podocyte cell body area on PAS stainings demonstrated a signif-
icant reduction in podocyte area following UCH-L1 inhibition in PHN
rats (Fig. 3B). Supporting, the biochemical parameter of hypertrophy
(protein/gDNA ratio) was decreased in LDN57444 treated compared
to untreated PHN glomeruli (Fig. 3C). The extent of subepithelial
immune deposits and local complement activation was similar in PHN
rats compared to PHN+LDN rats (Supplementary Fig. 1).
2.4. UCH-L1 over-expression increases podocyte hypertrophy by
accumulation of protein
Since UCH-L1 inhibition reduced total glomerular protein content
and podocyte hypertrophy in PHN rats, we evaluated whether UCH-L1
over-expression in cultured podocytes caused hypertrophy through
increased protein levels. We established an inducible over-expression
system using the doxycycline sensitive tet-on system, in order to control
for the extent of UCH-L1 protein increase in podocytes (Fig. 4). Differen-
tiated podocytes exhibited a concentration (Fig. 4A) and time-
dependent (Fig. 4B) over-expression of UCH-L1 in response to doxycy-
cline. Control podocytes (tet−, which lack the UCH-L1 insert in the
pRetroX-Tight plasmid) exhibited no increased UCH-L1 expression
upon doxycycline stimulation (Fig. 4C). For the following experiments
UCH-L1 induction was performed with 5 ng/ml doxycycline for 72 h,
conditions that induced amoderate and robust UCH-L1 over-expression.
The cell diameter was measured in non-adherent podocytes in an
automated cell counter. Over-expression of UCH-L1 signiﬁcantly in-
creased the cell diameter in comparison to un-induced control
Fig. 1. In human membranous nephropathy UCH-L1 is upregulated and p27Kip1 localizes to the cytoplasm in hypertrophic podocytes. A: Left panel: PAS staining of a control (interstitial
nephritis) and amembranous nephropathy (MGN) renal biopsy. Arrows: swollen podocytes inMGN. Right panel:Measurement of podocyte cell body area frompatientswithMGNversus
control (n= 6), *p b 0.0001. B: UCH-L1 (red) expression in a normal (control) and aMGN renal biopsy (a, b). Closed arrows: swollen UCH-L1 positive podocytes, open arrows: podocytes
without swelling and low to noUCH-L1 immunoreactivity, n=4, 6. C: P27Kip1 (green) andNephrin (red) expression in a renal biopsy from a normal (control) and aMGNpatient. Note the
increasedp27Kip1 staining in podocytes (*) especially in the cytoplasmof theMGNbiopsy.Nucleiwere counterstainedwith ToproIII (blue). Thenegative controlwas generated by omitting
the primary antibodies to Nephrin and to p27Kip1. D: Double immunoﬂuorescence against UCH-L1 (green) and p27Kip1 (red) inMGN. c= podocyte cytoplasm, n= podocyte, nuclei were
counterstained with DRAQ5 (blue). E: p27Kip1 gene expression was quantiﬁed in micro-dissected glomeruli from living donor subjects (LD, n = 6) and patients with MGN (n= 14). The
graph shows expression ratios of p27Kip1 normalized to 18S rRNA, n.s. = non signiﬁcant.
947F. Lohmann et al. / Biochimica et Biophysica Acta 1842 (2014) 945–958podocytes (Fig. 4D). Furthermore, UCH-L1 over-expression increased the
protein/gDNA ratio, whereas stable UCH-L1 knockdown or inhibition of
UCH-L1 hydrolase function decreased the protein/gDNA ratio in cultured
podocytes (Fig. 4E). To analyzewhether the elevated protein content was
due to a global increase of proteins and not due to a singular increase of
UCH-L1 protein levels in UCH-L1 over-expressing cells, Coomassie
stainings of 105 cells (Fig. 4F)were performed. Coomassie stainings dem-
onstrated that UCH-L1 over-expression induced an increase of a broadrange of proteins. Increased total protein levels could be due to increased
synthesis. Inhibition of de novo protein synthesis with cycloheximide
however did not signiﬁcantly prevent the increase of total protein content
in response to UCH-L1 over-expression in podocytes (Fig. 4G).
To investigate whether upregulation of p27Kip1, UCH-L1 and total
protein content also occurred in thepathological framework of antibody
mediated damage in cultured podocytes, podocytes were treated with
puriﬁed anti-podocyte (APN) antibodies or pre-immune (PI) control
Fig. 2. In experimental MGN both UCH-L1 and p27Kip1 are upregulated in hypertrophic podocytes. A: PAS stainings of control (co = pre-immune serum injected) and passive Heymann
nephritis (PHN) rat glomeruli 3 weeks after disease induction, n= 3. Note the swollen podocytes in PHN rats. B:Measurement of podocyte cell body area in PAS light micrographs of PHN
rats 3 weeks after disease induction versus control, *p b 0.0001, n = 3. C: Protein content normalized to DNA content from isolated glomeruli of perfused co and PHN rats 18 days after
disease induction as ameasure of cellular hypertrophy, n=6.D: UCH-L1 (red) expression in control and PHN rats 3 weeks after disease induction. Closed arrows: swollen UCH-L1 positive
podocytes, open arrows: podocyteswithout swelling and low to noUCH-L1 expression. E: Double immunoﬂuorescence for p27Kip1 (green) andNephrin (red). Nuclei were counterstained
with ToproIII (blue). Note prominent cytoplasmic p27Kip1 staining in PHN podocytes (*). F: Western blotting for p27Kip1 from total lysates of isolated glomeruli of control and PHN rats on
day 18. β-Actin of the same membrane was used to control for equal loading. G: ELISA for p27Kip1 from total lysates of isolated glomeruli of control and PHN rats on day 18, n = 6. H:
Quantitative PCR of p27Kip1 transcript levels in isolated glomeruli 18 days after induction of disease. Valueswere normalized to 18SmRNA, n= 3 rats per condition; n.s. = not signiﬁcant.
I: Double immunoﬂuorescence for UCH-L1 (green) and p27Kip1 (red) in PHN or control rats onweek3; nucleiwere counterstainedwithDRAQ5 (blue).Note cytoplasmic p27Kip1 staining in
UCH-L1 expressing swollen podocytes (closed arrows) and nuclear p27Kip1 staining in UCH-L1 negative podocyte (open arrow).
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increase of UCH-L1, p27Kip1 and total protein levels. Furthermore, con-
comitant inhibition of UCH-L1 hydrolase function signiﬁcantly
prevented the increase of total protein content in APN treated
podocytes.2.5. Total and cytoplasmic p27Kip1 levels are regulated by UCH-L1 in
experimental MGN
UCH-L1 inﬂuenced podocyte total protein content and hypertrophy
in vivo and vitro and co-localized with p27Kip1 in hypertrophic
Fig. 3. Podocyte hypertrophy and glomerular protein content are regulated by UCH-L1 in experimental MGN. UCH-L1 inhibition (LDN57444, 40 μg/kg BW over s.c. osmotic mini-pumps,
for 14 days) was commenced 4 days after disease induction in passive Heymann nephritis (PHN) and pre-immune serum injected control (co) rats. Kidneys and glomeruli were analyzed
on day 18. A: PAS stainings demonstrate decreased swelling of podocytes in PHN rats with UCH-L1 inhibition, n = 3–6 rats. B: Measurement of podocyte cell body area in PAS light mi-
crographs, *p b 0.0001 to control and to control+ LDN, **p b 0.0001 to PHN, n=3; 6. C:Measurement of protein content normalized toDNA content from glomerular lysates as ameasure
for cellular hypertrophy, n = 3; 6 rats per condition.
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inﬂuenced the homeostasis of p27Kip1 in podocytes in PHN. Quantiﬁca-
tion of p27Kip1 by ELISA demonstrated a signiﬁcant reduction of glomer-
ular p27Kip1 content in UCH-L1 inhibited PHN rats (Fig. 5A). Glomerular
p27Kip1 levels were reduced compared to control rat levels by UCH-L1
inhibition in PHNwithout affecting glomerular p27Kip1 transcript levels
(Fig. 5B). Immunohistochemical analyses demonstrated that the mea-
sured glomerular reduction of p27Kip1 content by UCH-L1 inhibition
was mostly attributed to podocytes in PHN glomeruli (Fig. 5C, upper
panel). Speciﬁcally, cytoplasmic p27Kip1 staining was reduced in PHN
glomeruli after UCH-L1 inhibition. Compartmentalization of p27Kip1
from the nucleus to the cytoplasm requires p27Kip1 phosphorylation at
threonine 198 (Thr198) [30]. Immunohistochemical analyses showed
an accumulation of pThr198–p27Kip1 in the cytoplasm of podocytes in
PHN rats, suggesting the increased nuclear export of p27Kip1 in PHN
as one possible cause of prominent cytoplasmic p27Kip1 expression
in PHN. Interestingly, the cytoplasmic pool of pThr198–p27Kip1 was
signiﬁcantly reduced by inhibition of UCH-L1 hydrolase activity in
PHN rats (Fig. 5C, lower panel). In order to quantitate cytoplasmic
p27Kip1 levels, cytoplasmic and nuclear fractions from glomerular ly-
sates were analyzed byWB. Cytoplasmic p27Kip1 levels increased sig-
niﬁcantly in PHN glomeruli and UCH-L1 inhibition signiﬁcantly
reduced the cytoplasmic p27Kip1 accumulation in PHN glomeruli
(Fig. 5D, left panel). WB did not show signiﬁcant changes in nuclear
p27Kip1 levels (Fig. 5D, right panel). Taken together, these datademonstrate that UCH-L1 inhibition speciﬁcally reduced cytoplasmic
p27Kip1 protein content in PHN.
2.6. UCH-L1 activity increases total and cytoplasmic p27Kip1 in cultured
podocytes
As in human and rodent MGN, over-expression of UCH-L1 in cul-
tured podocytes increased total p27Kip1 content (Fig. 6A), whereas sta-
ble knockdown of UCH-L1 via two distinct shRNAs reduced total
p27Kip1 levels (Fig. 6B). Since predominantly the cytoplasmic pool of
p27Kip1 was inﬂuenced by UCH-L1 inhibition in PHN, we quantiﬁed
the cytoplasmic and nuclear p27Kip1 contents by WB in cultured
podocytes with modiﬁed UCH-L1 expression (Fig. 6C, D). Over-
expression of UCH-L1 increased the cytoplasmic p27Kip1 and decreased
thenuclear p27Kip1 content (Fig. 6C left panel (1);D (1)),whereas stable
knockdown of UCH-L1 (Fig. 6C middle panel (2); D (2)) resulted in the
opposite distribution: decreased cytoplasmic p27Kip1 and increased nu-
clear p27Kip1 levels. Interestingly, chemical inhibition of UCH-L1 hydro-
lase activity (Fig. 6C, (3); D (3)) in UCH-L1 over-expressing podocytes
signiﬁcantly decreased cytoplasmic p27Kip1 levels but did not signiﬁ-
cantly affect the nuclear p27Kip1 content as seen in PHN rats treated
with LDN57444. Supporting, immunoﬂuorescent analyses demonstrat-
ed a prominent cytoplasmic p27Kip1 signal with a decreased nuclear
p27Kip1 expression in response to UCH-L1 over-expression, which was
reverted by inhibition of UCH-L1 hydrolase activity (Fig. 6E).
Fig. 4. Inducible UCH-L1 over-expression increases podocyte hypertrophy by accumulation of protein. Inducible overexpression of UCH-L1 in cultured podocytes was achieved using the
tet-on system as described in theMethods section. A: Concentration dependent increase of UCH-L1 protein is seen byWestern blotting after induction of expressionwith doxycyclin (dox)
for 4 days, β-actin was used as a loading control. B: Time-course of UCH-L1 induction. Upper panel: Western blotting for UCH-L1 and β-actin as a loading control. Lower panel: Densito-
metric analysis of UCH-L1 levels, *p b 0.01. C: Tet− control cells do not react to increasing concentrations of dox after 4 days. Lanes 9+ 10: positive control (tet+ cells with dox). D:Mea-
surement of cell diameter using a cell counter in trypsinized, non-adherent UCH-L1 tet-on cells without (w/o dox) or with induction of UCH-L1 overexpression for 72 h. E: Assessment of
the hypertrophy index in cultured podocytes with stable knockdown of UCH-L1 protein through shRNA technology (UCH-L1 KD), in induced UCH-L1 overexpressing podocytes (UCH-L1
OE) or in induced UCH-L1 overexpressing podocytes treatedwith the speciﬁc UCH-L1 inhibitor LDN57444 (LDN, 10 μM) for 72 h; n= 5–8 cell pellets per condition. Valueswere normal-
ized to respective controls (scrambled shRNA, -dox or DMSO treatment, respectively), *p b 0.05 to respective controls. F: Coomassie stainings of total podocyte lysates from105UCH-L1 tet-
on podocyteswith (tet+)with orwithout (w/o) induced UCH-L1 overexpression or from 105 control cells (tet−) treatedwith LDN57444 (LDN, 10 μM, 72 h) or vehicle. Protein levels are
increased upon UCH-L1 induction and decreased by UCH-L1 inhibition. G: Assessment of the hypertrophy index in podocytes with induced UCH-L1 overexpression after treatment with
cycloheximide (CHX 20 μg/ml) to block protein synthesis for 6 h; n=5 cell pellets per condition. Valueswere normalized to control (tet−with dox), n.s. non-signiﬁcant to EtOH. H and I:
Normal podocyteswere treatedwith pre-immune (PI) or anti-podocyte nephritis antibody (APN) for 24 h. H:Western blot and densitometry demonstrate increased levels of UCH-L1 and
p27Kip1 in APN treated podocytes, n= 2–3 pellets per condition, *p b 0.05 to PI (black bar). I: Measurement of total protein content (mg/ml) per cell demonstrates increased hypertrophy
of APN treated podocytes, which is decreased to PI levels by concomitant UCH-L1 inhibition with LDN57444 (5 μM, 24 h), *p b 0.05 to PI, **p b 0.05 to APN.
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export, decreased polyubiquitination and degradation in cultured podocytes
UCH-L1mediated cytoplasmic protein accumulation such as p27Kip1
could result from increased nuclear export and/or decreased poly-
ubiquitination and subsequent lesser degradation by the proteasome.Both require the in PHN observed p27Kip1 phosphorylation at Thr198
and/or Ser10, which is regulated by kinases such as AKT [30]. Since
UCH-L1 has been described to increase AKT activity through inhibition
of PHLPP1 phosphatase in tumor cells of UCH-L1 transgenic mice [31],
we evaluated the phosphorylation status of p27Kip1 at these AKT phos-
phorylation sites in podocytes. Over-expression of UCH-L1 increased
Fig. 5. Total and cytoplasmic p27Kip1 levels are regulated by UCH-L1 in experimental MGN. UCH-L1 inhibition (LDN57444, 40 μg/kg BW for 14 days) was commenced 4 days after disease
induction in passive Heymann nephritis (PHN) and pre-immune serum injected control (co) rats. All analyseswere performed on day 18 in shock frozen isolated glomeruli. A: Glomerular
p27Kip1 levels were measured by ELISA and B: glomerular p27Kip1 transcript levels were measured by qPCR. Values were normalized to 18S mRNA, *p b 0.05 to control. C: Upper panel:
Immunoﬂuorescence for p27Kip1 (green). Note the strong cytoplasmic p27Kip1 staining in untreated PHN rats. Lower panel: Phosphorylation of p27Kip1 at Thr198 is a signal for nuclear
export of p27Kip1. Immunoﬂuorescence for pThr198-p27Kip1 (green) demonstrates increased pThr198-p27Kip1 staining in the cytoplasm of a PHN podocyte. Nuclei were visualized with
DNA intercalating ToproIII (TIII, blue); *podocyte nucleus. D:Upper panel:Western blotting for p27Kip1 in cytoplasmic and nuclear fractions of isolatedglomeruli demonstrates cytoplasmic
accumulation of p27Kip1 in PHN rats, which is decreased by UCH-L1 inhibition. GapDH was used as a marker and as a loading control for the cytoplasmic fraction, Lamin B for the nuclear
fraction. Nuclear (nucl. ctr) or cytoplasmic (cyt. ctr) control lysate was loaded to demonstrate speciﬁc compartmentalization. Lower panel: Densitometric analysis of cytoplasmic and nu-
clear p27Kip1 levels normalized to respective loading controls, *p b 0.05.
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(Fig. 7A). Therefore the post-translational signal for nuclear export
and poly-ubiquitination of p27Kip1 was enhanced in response to UCH-
L1 over-expression.Nuclear export of p27Kip1 is in partmediated by binding of p27Kip1 to
JAB-1, in conjunction with UCH-L1 [28]. We therefore inhibited CRM1/
exportin 1 dependent nuclear export of p27Kip1 by Leptomycin B in
podocytes with or without UCH-L1 over-expression. Inhibition of
Fig. 6. UCH-L1 activity increases total and cytoplasmic p27Kip1 in cultured podocytes. UCH-L1 content was modulated by inducible over-expression of UCH-L1 by the tet-on system or by
stable shRNAmediated knockdown of UCH-L1 in cultured podocytes. Hydrolase activity of UCH-L1 was inhibitedwith the speciﬁc and reversible inhibitor LDN57444. A:Western blotting
for UCH-L1, p27Kip1 and β-actin to control for equal loading shows increased p27Kip1 levels with UCH-L1 induction. Right panel: Densitometric analysis of 3 independent experiments.
B: Western blotting for UCH-L1, p27Kip1 and β-actin in whole podocyte lysates with stable UCH-L1 knockdown (sh627 and sh817) or with stable expression of scrambled shRNA (co).
C: Western blotting for UCH-L1, p27Kip1, Lamin B and GapDH in cytoplasmic and in the corresponding nuclear fractions. Left panel (1): Induced UCH-L1 expression for 72 h results in cy-
toplasmic p27Kip1 accumulation and indecreased nuclear p27Kip1 levels. Middle panel (2): Stable knockdown (KD) of UCH-L1 reduces cytosolic p27Kip1 levels and increases nuclear p27Kip1
levels (co = scrambled shRNA expression). Right panel (3): UCH-L1 hydrolase inhibition (LDN57444, LDN, 72 h) in podocytes with induced UCH-L1 expression results in decreased
cytosolic p27Kip1 and unchanged nuclear p27Kip1 levels. D: Densitometric analysis of Western blots (1–3) from C including additional 3–6 samples. Left panel: cytoplasmic p27Kip1 levels
normalized toGapDH levels. Right panel: Ratio of cytoplasmic p27Kip1/GapDH levels to nuclear p27Kip1/LaminB levels. (1)UCH-L1 tet-on cellswithout (blackbar) orwith (white bar) UCH-
L1 induction; (2) UCH-L1 knockdown cells (KD), black bar= scrambled shRNA (control), white bar=UCH-L1 speciﬁc sh627 and sh817 (knockdown); (3) UCH-L1 tet-on cells with UCH-
L1 induction treated with DMSO (black bar) or 50 μM LDN57444 for 24 h (white bar), *p b 0.05 to respective controls (black bars). E: Immunoﬂuorescence for p27Kip1 (green) in UCH-L1
tet-on cells without (a) orwith (b–d) inducedUCH-L1 expression for 72 h. Cellswere grown to conﬂuence to induce proliferation stop by contact inhibition. Note nuclear p27Kip1 (arrows)
in (a) and (c) and cytoplasmic p27Kip1 accumulation in (b) and (d).
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plasmic p27Kip1 levels in UCH-L1 over-expressing podocytes (Fig. 7B) by
WB. Cytoplasmic JAB-1 levels were signiﬁcantly decreased whereas
UCH-L1 levels remained unchanged by Leptomycin B treatment. Further
investigations demonstrated that UCH-L1 did not inﬂuence JAB-1content or localization in podocytes (Supplementary Fig. 2). Therefore,
UCH-L1 induced p27Kip1 cytoplasmic accumulation in podocytes inde-
pendently of JAB-1 associated nuclear export.
Since nuclear export of p27Kip1 was increased by UCH-L1 over-
expression, we additionally analyzed the contribution of altered p27Kip1
Fig. 7. UCH-L1 induces cytoplasmic p27Kip1 accumulation by increased nuclear export, decreased polyubiquitination and degradation in cultured podocytes. Inducible overexpression of
UCH-L1 in cultured podocytes was achieved by using the tet-on system as described in the Methods section. A: Phosphorylation of p27Kip1 at Thr198 and/or Ser10 is a signal for nuclear
export. Total cell lysates were loaded and adapted to p27Kip1 content. Western blotting for pThr198-p27Kip1 and pSer10-p27Kip1 demonstrates increased phosphorylation of p27Kip1 at
Thr198 in UCH-L1 overexpressing (+dox) podocytes. B: Analysis, whether increased nuclear export of p27Kip1 contributes to the increased cytoplasmic p27Kip1 content in response to
UCH-L1 overexpression. Nuclear export was inhibited with Leptomycin B (LepB, 3 h). Western blotting for UCH-L1, p27Kip1 and JAB-1 in the cytoplasmic fraction of induced (+dox) or
un-induced (−dox) UCH-L1 tet-on cells. Note the decreased cytoplasmic p27Kip1 levels in UCH-L1 overexpressing cells (lanes 3 and 4) due to inhibition of nuclear export. Right panel:
Densitometric analysis of cytoplasmic p27Kip1 levels normalized to GapDH, *p b 0.05. C: Total p27Kip1 was immune-precipitated fromwhole cell lysates of UCH-L1 tet-on podocytes with-
out andwithUCH-L1 induction and in tet− control cells. To prevent thedegradation of pUB-p27Kip1 by theproteasome, cellswere treatedwith the reversible proteasome inhibitorMG132
(MG132, 100 μM, 1 h). For inhibition of UCH-L1 hydrolase function cells were treated with LDN5477 (LDN, 20 μM, 24 h). Poly-ubiquitinated p27Kip1 (pUB-p27Kip1) was ﬁrst detected by
Western blotting for ubiquitin (ms-α-UB). Thereafter p27Kip1 was detected on the samemembranewith a rabbit-α-p27Kip1 antibody. A nonspeciﬁc rabbit antibody (rb) was used to con-
trol for unspeciﬁc binding. Note thedecreased pUB-p27Kip1 levels inUCH-L1 overexpressingpodocytes (lane 2 versus 1),which are not rescuedbyproteasomal inhibition (lane 5 versus 4),
which are however rescued by inhibition of UCH-L1 hydrolase function (lane 9 versus 8). D: Inhibition of proteasomal degradation (MG132, 100 μM, 1 h) in UCH-L1 over-expressing
podocytes leads to a stabilization of p27Kip1 in the cytoplasmic fractions. Additional inhibition of UCH-L1 hydrolase activity (LDN57444, 10 μM, 24 h) leads to a further increase of cyto-
plasmic p27Kip1content. Lower panel: Densitometric analysis of cytoplasmic p27Kip1 levels normalized to β-actin, *p b 0.05 to DMSO, **p b 0.05 to MG132.
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immune-precipitated from cultured podocytes with or without induced
UCH-L1 over-expression and the amount of poly-ubiquitinated p27Kip1
(poly-Ub-p27Kip1) was assessed within the immune-precipitated
p27Kip1 fraction (Fig. 7C). UCH-L1 over-expression reduced the amount
of poly-Ub-p27Kip1 when equal amounts of immune-precipitated
p27Kip1 were loaded (Fig. 7C, left panel). The reduced amount of
poly-Ub-p27Kip1 upon UCH-L1 over-expression could result from in-
creased degradation through the proteasome. We therefore inhibited
proteasomal degradation by applying the reversible proteasome inhibi-
tor MG132 in over-expressing and non-over-expressing control cells
(Fig. 7C, middle panel). However, podocytes with increased UCH-L1 ex-
pression exhibited less poly-Ub-p27Kip1 in comparison to control cells,
suggesting decreased poly-ubiquitination and subsequently decreased
degradation of p27Kip1 as a reason for increased cellular p27Kip1 levels.
If UCH-L1 hydrolase function was involved in reducing poly-
ubiquitination of p27Kip1, then inhibition of UCH-L1 hydrolase function
should result in increased poly-Ub-p27Kip1 levels. In order to evaluatewhether UCH-L1 enzymatic activity was involved in reducing poly-Ub-
p27Kip1 levels, poly-Ub-p27Kip1 levels were ﬁrst stabilized by MG132
treatment followed by an additional inhibition of UCH-L1 hydrolase
activity (Fig. 7C, left panel). Inhibition of UCH-L1 hydrolase function
resulted in comparable amounts of poly-Ub-p27Kip1 in podocytes with-
out or with UCH-L1 over-expression, suggesting an involvement of
UCH-L1 enzymatic activity in reducing poly-Ub-p27Kip1 levels. WB ex-
periments conﬁrmed these ﬁndings. Firstly, we tested whether
proteasomal inhibition increased cytoplasmic p27Kip1 levels by stabiliza-
tion of p27Kip1 targeted for degradation (Fig. 7D). Indeed, MG132 treat-
ment increased cytoplasmic p27Kip1 levels. Secondly, if inhibition of
UCH-L1 hydrolase activity restored the pool of p27Kip1 targeted for
proteasomal degradation (poly-Ub-p27Kip1), then UCH-L1 inhibition
should result in a further increase of p27Kip1 content in MG132 treated
podocytes asmore p27Kip1 is being targeted for proteasomal degradation
and subsequently stabilized by proteasomal inhibition. Accordingly,
UCH-L1 inhibition resulted in a further stabilization of p27Kip1 levels in
podocytes with inhibited proteasomal degradation (Fig. 7D).
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culture
UCH-L1 induces an increase of protein levels and hypertrophy in
podocytes by accumulation of proteins in the cytoplasm, as shown for
p27Kip1. However, hypertrophymediated by p27Kip1 is thought to result
from a G1/S phase cell-cycle arrest. We therefore analyzed whether,
besides increasing protein content, UCH-L1 induced a G1 arrest in
podocytes. Differentiated podocytes were synchronized and the distri-
bution of cell-cycle phases in podocytes after 72 h of UCH-L1 induction
or with stable knockdown of UCH-L1was determined bymeasuring the
cellular DNA content by FACS in comparison to control cells (Fig. 8A).
Surprisingly, the proportion of podocytes in G1 phase was signiﬁcantlyFig. 8. UCH-L1 expression increases podocyte turnover and migration in culture. Inducible over
knockdown of UCH-L1 expression (KD) was achieved by stable overexpression of shRNA627 d
contentwas stainedwith propidium iodide. The amount of propidium iodide,which reﬂects the
controls. Left panel: in UCH-L1 overexpressing cells (tet-on + 72 h dox) and in respective cont
Right panel: in podocytes with stable knockdown of UCH-L1 with shRNA627 or scrambled
recounted after 72 h of culture, n = 3 per condition. C: Quantiﬁcation of apoptotic podocytes
were counted. UCH-L1 OE= induced UCH-L1 overexpression for 72 h; UCH-L1 KD= stable U
shRNA). D: Formigration assays, awoundwas set in 80–90% conﬂuent tet+podocytes andwou
expression, *p b 0.01, n = 6 per condition. E: Representative micrographs of f-actin stainings (Preduced in UCH-L1 over-expressing podocytes. Furthermore, the pro-
portion of cells in subG0 (mostly apoptotic cells and cell debris) was in-
creased, suggesting a decreased amount of quiescent cells throughUCH-
L1 induction. Contrariwise, knockdown of UCH-L1 increased the per-
centage of cells in G1 phase and decreased the subG0 population. We
therefore determined podocyte turnover as described in the Method
section. UCH-L1 over-expression resulted in a signiﬁcant increase of
podocyte numbers compared to control conditions (Fig. 8B). In line
with the increased subG0 fraction measured in cell-cycle analyses,
over-expression of UCH-L1 resulted in increased apoptotic (TUNEL pos-
itive) cells. In contrast, stable knockdown of UCH-L1 reduced the per-
centage of apoptotic cells (Fig. 8C). In addition to enhancing podocyte
turnover, UCH-L1 over-expression increased the migratory potentialexpression of UCH-L1 in cultured podocytes was achieved by using the tet-on system and
irected against UCH-L1. A: Cell cycle distribution in synchronized podocytes. Nuclear DNA
cell cycle phase per cell, wasmeasured by FACS inn=6 samples per condition, *p b 0.05 to
rol cells (tet−with 72 h dox) or UCH-L1 tet-on cells without induction (tet-on w/o dox).
shRNA (control). B: Quantiﬁcation of podocyte proliferation. 105 cells were plated and
72 h after passaging. DNA breaks were stained using the TUNEL assay and apoptotic cells
CH-L1 knockdown versus respective control conditions (tet−with 72 h dox or scrambled
nd closurewas assessed after 24 hwith (+dox) orwithout (w/o dox) induction of UCH-L1
halloidin) of podocytes at the wound border (w) of migration assay, magniﬁcation 400×.
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size was smaller in UCH-L1 over-expressing cells in comparison to con-
trol podocytes. Additionally, inhibition of UCH-L1 hydrolase activity
with LDN57444 nearly abrogated the potential to close the wound in
UCH-L1 over-expressing podocytes. These data demonstrate that the
migratory capacity of cultured podocytes was inﬂuenced by UCH-L1
and its enzymatic activity. The prerequisite for cellularmigration is a cy-
toskeletal rearrangement. We therefore visualized the actin-
cytoskeleton by staining against f-actin (Fig. 8E). Whereas podocytes
without UCH-L1 induction exhibited long slender processes and a cell
density of 70–80% at thewound edge, UCH-L1 over-expression resulted
in a denser podocyte population (80–90% cell density) with short and
broad membrane protrusions. Additional inhibition of UCH-L1 hydro-
lase function resulted in a cell density of 70–80% and a reduced forma-
tion of protrusions and processes at the wound edge.
In summary, these data demonstrate that UCH-L1 activity in
podocytes increased protein levels and hypertrophy by accumulation
of proteins in the cytoplasm, as shown for p27Kip1. This was accompa-
nied by a reduction of podocytes in the G1-phase, increased cellular
turnover, migration and cytoskeletal rearrangement.
3. Discussion
In this workwe demonstrate that the neuronal deubiquitinase UCH-
L1 induces podocyte hypertrophy in rodent MGN by increasing total
protein content in podocytes. Podocyte hypertrophy was observed by
others and us in human [3] and rodent membranous nephropathy
[19] and proposed to be a result of G1/S-phase arrest [14,19,32]. Upon
entering arrest in G1 phase, cells increase the ratio of protein to gDNA
content per cell, resulting in increased cell size. In this work, we ob-
served that UCH-L1 increased the protein/gDNA ratio in vivo and
vitro, but not by initiating a G1/S-phase arrest in podocytes. Other pos-
sible explanations exist for the UCH-L1 dependent increase of protein/
gDNA ratio. The observed increased protein/gDNA ratio may also result
from increased de novo protein synthesis in podocytes. However, inhi-
bition of de novo protein synthesis did not abolish the UCH-L1 depen-
dent increase of protein/gDNA ratio. Increased protein levels could
also result from altered protein degradation. Firstly, protein degradation
systems could be overwhelmed, resulting in the accumulation of dys-
functional proteins. Secondly, degradation of proteins targeted by
poly-ubiquitination could be prevented, e.g. by deubiquitinating en-
zymes such as UCH-L1, resulting in stabilization and increased levels.
In line with the idea that an increased protein/gDNA ratio could be
due to an overwhelmed degradation system were the observations
that injured podocytes in human [5] and rodent MGN [6] accumulate
ubiquitin and poly-ubiquitinated proteins [6]. Poly-ubiquitination des-
ignates proteins for proteasomal or lysosomal degradation, depending
on the ubiquitin linkage used. Usually damaged proteins, or proteins
that aremeant to be downregulated are poly-ubiquitinated and degrad-
ed. We were able to demonstrate that modulation of UCH-L1 hydrolase
activity reduced the accumulation of poly-ubiquitinated proteins in ro-
dent MGN by increasing proteasomal activity [6]. Therefore, we argue
that UCH-L1 dependent podocyte hypertrophy in vitro and in rodent
MGN is in part the result of increased protein levels due to altered
protein degradation in podocytes.
The question remains whether the accumulating proteins in hyper-
trophic podocytes in response to UCH-L1 are mostly dysfunctional
poly-ubiquitinated proteins, or whether functional proteins also
accumulate, potentially enhancing podocyte injury. To challenge this
question, we analyzed the homeostasis of the “model” protein cyclin-
dependent kinase inhibitor p27Kip1. Firstly, p27Kip1 levels are primarily
regulated by post-translational modiﬁcations, which ultimately lead to
proteasomal degradation [30]. Secondly, p27Kip1 has been viewed as a nu-
clear proteinwith the function of modulating cyclin/cyclin-dependent ki-
nase complexes and cell cycle progression from G1 to S-phase [30].
Through these actions, p27Kip1 was hypothesized to retain podocytes ina quiescent, non-proliferative state in MGN [33] or induce glomerular/
podocyte hypertrophy in diabetic nephropathy [34] and PHN [19]. Our
investigations demonstrated that concomitantly to de novo UCH-L1 ex-
pression in podocytes with increased cell size in human and rodent
MGN, expression of p27Kip1 was increased. Especially cytoplasmic levels
of p27Kip1 were modulated by podocyte UCH-L1 content and enzymatic
activity. These increased levels of cytoplasmic p27Kip1 argue against the
idea that podocyte hypertrophy in MGN is solely an effect of nuclear
p27Kip1 on the cell cycle resulting in a G1/S-phase arrest and hypertrophy.
An additional contribution of a G1/S-phase arrest to UCH-L1 induced hy-
pertrophy cannot be excluded since p27Kip1 protein was also detectable
in nuclear fractions in vivo and vitro. However, the failure of UCH-L1
over-expression to induce a G1 arrest in cultured podocytes despite in-
creased total p27Kip1 levels and hypertrophy argue against the
established role of nuclear p27Kip1 in the genesis of podocyte hypertro-
phy in MGN.
We were able to demonstrate that UCH-L1 induced total and cyto-
plasmic accumulation of p27Kip1 via two mechanisms: 1. by increased
nuclear export and 2. by decreased poly-ubiquitination and decreased
proteasomal degradation. In all systems that were evaluated, transcrip-
tional levels of p27Kip1 were not changed, indicating post-translational
mechanisms of p27Kip1 regulation through UCH-L1. P27Kip1 belongs to
the family of “intrinsically unstructured” [35] proteins and therefore
presents a large number of possible conﬁrmations and interactions
with a multitude of targets. It was demonstrated in lung tumor cells
that UCH-L1 could form hetero-trimeric complexes through association
with JAB-1, a multifunction protein, and p27Kip1 [28]. This interaction of
UCH-L1 with JAB-1 is thought to facilitate nuclear-cytoplasmic translo-
cation and thus promote cytoplasmic proteasomal degradation of
p27Kip1. We were able to demonstrate JAB-1 expression in podocytes
but UCH-L1 levels and activity in vivo and in vitro in podocytes inﬂu-
enced neither JAB-1 levels nor its localization. Functionally, inhibition
of nuclear export of p27Kip1 resulted in a slight but non-signiﬁcant re-
duction of cytoplasmic p27Kip1 levels in podocytes. Our results suggest
that increased nuclear export of p27Kip1 could be one mechanism of
UCH-L1 dependent cytoplasmic p27Kip1 accumulation in podocytes
and that molecules other than JAB-1 might be implicated.
We hypothesized that UCH-L1 prevented degradation of p27Kip1.
Several ﬁndings supported this hypothesis: First we demonstrated,
that poly-ubiquitination of p27Kip1 was reduced in UCH-L1 over-
expressing podocytes. Furthermore, inhibition of UCH-L1 hydrolase ac-
tivity resulted in normalized levels of poly-ubiquitinated p27Kip1 and re-
duced cytoplasmic p27Kip1 levels indicating re-established proteasomal
degradation of p27Kip1. Whether the decreased poly-ubiquitination was
due to direct deubiquitination of p27Kip1 by UCH-L1 or was mediated
through other DUBs remains to be investigated. Due to its structure,
UCH-L1 is presumed to interact with small substrates [36] and to have
the ability to hydrolyse distal ubiquitin moieties of small proteins such
as small adduct of ubiquitin or ubiquitinated pro-proteins [10,37,38].
However, no speciﬁc substrates to UCH-L1 have been identiﬁed to
date, despite continuous efforts.
UCH-L1 over-expression induced enhanced podocyte turnover and
motility, which might be a result of increased cytoplasmic levels of
functional p27Kip1. However, it has to be taken into account that other
factors have been shown to inﬂuence the migratory capacity of
podocytes [39,40]. Besides its well-established role as a cyclin/cyclin-
kinase inhibitor, studies have demonstrated additional roles of p27Kip1
outside of the nucleus, such as modulation of the structure of the
cytoskeleton, cell contractility and motility [41–43]. These actions are
the result of p27Kip1 interactions with various cytoskeletal regulators in
the cytoplasm, including RhoA [41], Rac [42], Stathmin [43] and Grp2
[44]. Additionally, some tumors show low levels of nuclear p27Kip1
with a corresponding increase in cytoplasmic p27Kip1 as seen in UCH-
L1 over-expressing podocytes. This subcellular redistribution of p27Kip1
in tumors is associated with poor clinical outcome in patients [45,46]. It
is therefore intriguing to speculate that the UCH-L1 induced cytoplasmic
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creased turnover and/or motility.
Taken together our data demonstrate that UCH-L1 induces podocyte
hypertrophy by accumulation of functional proteins such as p27Kip1 via
altered post-translational modiﬁcation in the cytoplasm of injured
podocytes in human and rodent MGN. Aberrant protein degradation
may be a novel pathophysiology in MGN and modiﬁcation of both
UCH-L1 activity and levels in MGN could be a new therapeutic avenue
in MGN.
4. Materials and methods
4.1. Antibodies
Primary antibodies used for the study are: p27Kip1 rabbit pAB (Cell
Signaling, WB 1:1000, IHC 1:100); p27Kip1 (D69C12) XP™ rabbit mAB
(Cell Signaling, 1:100 IF); pThr198-p27Kip1 (ab64949) rabbit pAB
(Epitomics, WB 1:1000, IHC, 1:100); pS10-p27Kip1 (ab62364) rabbit
mAB (Epitomics, WB 1:1000, IHC, 1:100); Nephrin guinea pig pAB
(Acris, IHC 1:100); UCH-L1 mouse mAB (Abcam, 13C4; IHC 1:50, WB
1:500); JAB-1 rabbit pAB (LifeSpan Bioscience, WB 1:1000); Ubiquitin
mouse mAB (Millipore, Ubi-1, WB 1:1000); GapDH goat pAB (Santa
Cruz, I-19, WB 1:250); β-actin mouse mAB (Sigma, WB 1:3000);
Lamin B goat pAB (Santa Cruz, C-20,WB1:1000). All secondary antibod-
ies used were either biotinylated or HRP conjugated afﬁnity puriﬁed
donkey antibodies (Jackson ImmunoResearch).
4.2. Passive Heymann nephritis (PHN)
PHNwas induced in 200–250 gmale Sprague–Dawley rats by i.v. in-
jection of 500 μl and the following day of 750 μl of a sheep anti-FX1A an-
tiserum [47] or control sheep pre-immune serum. For UCH-L1
inhibition, LDN57444 (Calbiochem, 40 μg/kg body-weight in DMSO)
was introduced in 2 ml Alzet osmotic mini-pumps, which were im-
planted s.c. on day 4 after the last serum injection. Perfused glomeruli
were isolated on day 18 using conventional sieving for further analyses.
All animal experiments were performed according to the national and
institutional animal care and ethical guidelines and have been approved
by the local ethics committees (82/06, 107/09 and 2/13).
4.3. Cell culture
Murine podocytes (a kind gift from K.H. Endlich, Greifswald) were
cultured as described [48] in tetracycline-free culture medium contain-
ing 10% FCS (PAN Biotech). For proteasomal inhibition podocytes were
cultured with 1 μMMG132 (Calbiochem) in DMSO for 1 h, for UCH-L1
inhibition with 5–50 μM LDN57444 (Calbiochem) in DMSO for 24 h,
for inhibition of nuclear exportwith 3 nM Leptomycin B (ENZO, Life Sci-
ence) for 3 h in ethanol. For control, cells were cultured with vehicle
only. Podocytes were cultured with puriﬁed polyclonal sheep anti-
podocyte nephritis antibody or pre-immune serum [29] 0.5% for 24 h.
For inducible overexpression of UCH-L1, the Retro-X™ Tet-On Ad-
vanced Inducible Expression System (Clontech) was used as described
[49]. To generate the UCH-L1 tet-on cells, podocytes were transduced
with the pRetroX-Tet-On Advanced vector and with the pRetroX-
Tight-Pur-UCH-L1 vector. For the generation of negative control cells
(tet−), podocyteswere transducedwith the pRetroX-Tet-OnAdvanced
vector and the pRetroX-Tight-Pur empty vector. For induction of UCH-
L1 overexpression, UCH-L1 tet-on or tet− podocytes were cultured
with 0–50 ng/ml doxycycline. For stable knockdown experiments,
shRNA to murine UCH-L1 (shRNA627 and shRNA817) or scrambled
shRNA for control was overexpressed in podocytes as described before
[6]. For the assessment of apoptosis, TUNEL assay (Chemicon) was per-
formed in cultured podocytes and total cell and TUNEL positive cells
were counted in 10 visual ﬁelds (200×). For the assessment of podocyte
proliferation, equal cell numberswere plated and trypsinized after 72 h.Dead cells were stained with 0.1% Trypan Blue (Gibco) and viable cells
were counted in a Neubauer chamber. For the assessment of cell-cycle
distribution by FACS, podocyteswere synchronized by serum starvation
for 24 h, trypsinized, ﬁxed in 70% ethanol and treated with RNase
(60 U/mg, 10 min, Sigma). DNA was stained with propidium iodide
(1 mg/ml, 10 min, Molecular Probes). DNA content per cell was mea-
sured by FACS in a BD LSR II and analyzedwith FlowJo. Formigration as-
says, 104 cells per well of a 6-well plate were plated for 24 h. A deﬁned
wound was applied by scratching the cell layer with a 1 ml pipette tip
and cells were incubated for another 24 h.Wound closurewas analyzed
by phase-contrast-microscopy and quantiﬁed using an AxioVision light
microscope (Zeiss) using the AxioVision software at 100×.
4.4. Assessment of hypertrophy
Cellular or glomerular protein lysateswere obtained by lysis in 0.5M
Tris–HCl, pH 8.5, 1MNaCl, 0.5M EDTA, and 10% SDS. RNAwas removed
by RNase treatment (Sigma, 60 U/mg) for 2 1/2h at 55 °C. DNAwaspre-
cipitated from 50 μg of protein lysate (determined by standard BCA
tests) via ethanol precipitation and quantiﬁed in a NanoDrop spectro-
photometer. The ratio of protein/DNA was calculated and plotted.
4.5. Human specimen collection
The study was conducted according to the Declaration of Helsinki
principles with approval from the local ethics committee. Tissue
samples were obtained from the Department of Renal Pathology of
the University Medical Center Hamburg-Eppendorf.
4.6. Histological analysis and measurement of podocyte area
Kidneyswere ﬁxed in 4% paraformaldehyde and embedded in paraf-
ﬁn and further processed for periodic acid Schiff (PAS) staining as de-
scribed [50]. For the measurement of podocyte area, planimetric
examinations were performed onmicrographs taken at a magniﬁcation
of 400×. The podocyte cell body outlines of consecutively encountered
podocytes were traced and the area of individual podocyte cell bodies
was evaluated using the ImageJ image analysis system [51]. Percent
area difference was calculated as n [area] / mean [area control] ∗ 100.
4.7. Immunohistochemistry
1 μmparafﬁn sectionswere deparafﬁnized and antigen retrievalwas
performed bymicrowave boiling (10mM citrate buffer pH 6.1). Unspe-
ciﬁc binding was blocked (5% horse serum (hs), Vector, 30 min RT).
Primary antibody incubations (5% hs o/n, 4 °C) were followed by incu-
bation with biotinylated or AF488- or Cy3-coupled secondary antibod-
ies (1:400, 30 min, RT). Color development was performed with the
ABC-AP kit (Vector) or the TSA kit (NEN) with neufuchsin and nuclei
were counterstained with hematoxylin for IHC or with DRAQ5 or
ToproIII (both molecular probes) for IF. Stainings were analyzed using
a confocal microscope LSMmeta5 (Zeiss) or the AxioVision light micro-
scope (Zeiss) using the AxioVision or LSM software.
4.8. Nuclear-cytoplasmic fractionation
Nuclear-cytoplasmic fractionation was performed using the tech-
nique of sequential lysis [52]with twodifferent buffers. The cytoplasmic
fraction was obtained by disrupting cells with a buffer containing 1%
NP-40, 150mMNaCl, 50mMHepes, 1mM sodium ﬂuoride, 1mM sodi-
um vanadate, 100 nM calyculin A, complete protease inhibitor (Roche)
for 30 min on ice followed by centrifugation at 7000 rcf. The remaining
pellet was washed 3× in PBS and lysed in 0.1% SDS, 0.5% sodium
deoxycholate, 150 mM NaCl, 50 mM Hepes, 1 mM sodium vanadate,
1 mM NaF, complete protease inhibitor, and 100 nM calyculin A for 1
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and cleared by centrifugation at 16,000 rcf for 10 min.
4.9. Immunoblot and immune-precipitation
Immunoblots were performed as described previously [53]. Brieﬂy,
samples were lysed in T-PER (Pierce) (1mM sodium ﬂuoride, 1 mM so-
dium vanadate, and 100 nM calyculin A, complete (Roche)) and dena-
tured with 4× LDS. Samples were separated on a 4–12% Bis–Tris
NuPage gel (Invitrogen) in NuPage running buffer. Protein transfer
was performed in transfer buffer (50 mM Tris base, 0.192 M glycine in
ddH2O) in a NovexMini Cell (Invitrogen). PVDFmembranes (Millipore)
were blocked (3% nonfat milk) prior to incubation with primary anti-
bodies diluted in Superblock Blocking Reagent (Pierce). Bindingwas de-
tected by incubationwithHRP-coupled secondary antibodies (1:10.000,
3%nonfatmilk). Protein expressionwas visualizedwith ECL SuperSignal
(Pierce) on a Biomax Light Film (Kodak) and analyzed using software
from ImageJ [51]. For p27Kip1 immune-precipitation the μMACS™ Pro-
tein A/GMicroBeads Kit (Miltenyi Biotec) was used.Whole cell extracts
were adjusted to a concentration of 200 μg in 1 ml 1× lysis buffer 1%
Triton X-100, 150 mM NaCl, 50 mM Tris–HCl, pH 7.4, 1 mM EDTA, 1%
NP-40, 0.25% sodium-deoxycholate and complete protease inhibitor
cocktail (Roche). Pre-clearing was performed using 30 μl ProteinG se-
pharose beads (Sigma), the IP with 4 μg α-p27Kip1 pAB antibody o/n at
4 °C. Negative controls were performed with 7.5 μg nonspeciﬁc rabbit
IgG (Sigma). For magnetic labeling, 50 μl of the Protein A/GMicroBeads
was added (30 min at 4 °C). Magnetically labeled p27Kip1 was bound in
μ columns and washed with 4× with 200 μl IP buffer. Immune-
precipitated p27Kip1 was eluted by adding 50 μl of pre-heated (95 °C)
1×SDS to the μ columns. Poly-ubiquitination of p27Kip1 was then ana-
lyzed by WB in 15 μl.
4.10. ELISA against p27Kip1
P27Kip1 concentrationwas determined from glomerular lysates using
a standard ELISA kit against p27Kip1 (R&D systems). Brieﬂy, isolated glo-
meruli were lysed and weight-adapted in WB TPER lysis buffer. P27Kip1
content was measured in 50 μl of glomerular lysate and normalized to
total protein content determined by standard BCA kit measurement.
4.11. Quantitative PCR analysis
Total messenger RNA was isolated from shock-frozen rat glomeruli
isolated by conventional sieving with the RLT Plus Kit (Qiagen) and
1 μg was reverse transcribed with a random hexamer primer
(Invitrogen) and MMLV reverse transcriptase (NEB). qPCR was per-
formed with an AbiPrism NN8860 using SYBR Green [54]. The exon
spanning rat primers used were as follows: p27Kip1 fw 5′-GTGGACCC
AAAGACTGATCC-3′; p27Kip1 rev 5′-GTGGACCAAATGCCTCAGTC-3′. 18S
was used as an internal control. Relative quantiﬁcation of gene expres-
sion was calculated using the ΔΔCT method. Human renal biopsies
from patients with membranous nephropathy (MGN, n= 14) and con-
trols (living donors, LD, n = 6) were collected within the framework of
the European Renal cDNA Bank — Kröner-Fresenius Biopsy Bank [55].
The clinical characteristics of the used patient cohort are listed in
Supplementary Table 1. Diagnostic renal biopsies were obtained from
patients after informed consent and with approval of the local ethics
committees. Following renal biopsy, the unﬁxed tissue was transferred
to an RNase inhibitor and manually micro-dissected into glomerular
and tubulointerstitial compartments. Total RNA was isolated from
micro-dissected glomeruli, reverse transcribed, and linearly ampliﬁed
according to a protocol previously reported. Real-time RT-PCR was per-
formed as reported earlier [56]. Pre-developed TaqMan reagents were
used for human p27Kip1 (NM_004064), as well as the reference genes,
18S rRNA and GAPDH (Applied Biosystems). The expression of thecandidate gene was normalized to the reference genes. The mRNA
expression was analyzed by standard curve quantiﬁcation.
4.12. Statistics
Values are expressed as means ± SEM; n refers to the number of
animals or individual measurements in separate samples. Differences be-
tweenmultiple experimental groupswere compared by a Kruskal–Wallis
analysis with post hoc analysis; the Mann–Whitney U-test was used to
compare single groups. Paired Student's t-test was used to compare
mean values within one experimental series, unpaired Student's t-test
for the comparison of mean values of different experimental series. A p
value of 0.05 or less was accepted as statistically signiﬁcant.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.02.011.
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